RPCA
FOLD

Running Point Capital Advisors’s Amicus Therapeutics FOLD Stock Holding History

Running Point Capital Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,000
Closed -$122K – 171
2022
Q4 		$122K Hold
10,000
– – 0.08% 124
2022
Q3 		$104K Hold
10,000
– – 0.07% 127
2022
Q2 		$107K Sell
10,000
-408
-4% -$3.36K 0.07% 128
2022
Q1 		$99K Buy
+10,408
New +$97.6K 0.06% 137

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Running Point Capital Advisors's FOLD Position: Q1 2023 in Review

Running Point Capital Advisors sold out of Amicus Therapeutics (FOLD) in Q1 2023, closing a stake of 10,000 shares — an estimated $122K sold.

Running Point Capital Advisors first reported a position in FOLD in Q1 2022 and held it in 4 quarters. The position peaked at $122K in Q4 2022. 226 funds tracked by Wall St. Rank hold FOLD as of Q1 2023.

  • Running Point Capital Advisors reported no remaining Amicus Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Running Point Capital Advisors sold 10,000 Amicus Therapeutics shares in Q1 2023, an estimated $122K.
  • Running Point Capital Advisors first reported a position in Amicus Therapeutics in Q1 2022 and held it in 4 quarters.
  • Running Point Capital Advisors's Amicus Therapeutics position peaked at $122K in Q4 2022.
  • 226 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2023.

Based on Running Point Capital Advisors's 13F filing for Q1 2023, filed 10 May 2023.